x

Posted 10 February, 2023

Eiger BioPharmaceuticals, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:EIGR in a 8-K filed on 10 February, 2023.


  On February 6, 2023, Eiger BioPharmaceuticals, Inc. (the "Company") entered into a Separation Agreement and General Release (the "Separation Agreement") with David Cory, the Company's former President and Chief Executive Officer, in connection with Mr. Cory's previously announced resignation from the Company on December 14, 2022 (the "Separation Date").  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Eiger BioPharmaceuticals, Inc.
Health Care/Life Sciences • Biotechnology
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
Market Cap
$9.17M
View Company Details
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


Entry into Separation Agreement with David Cory 

On February 6, 2023, Eiger BioPharmaceuticals, Inc. (the "Company") entered into a Separation Agreement and General Release (the "Separation Agreement") with David Cory, the Company's former President and Chief Executive Officer, in connection with Mr. Cory's previously announced resignation from the Company on December 14, 2022 (the "Separation Date"). 

Pursuant to the Separation Agreement, Mr. Cory will be entitled to receive, among other things, (i) $1,504,800, which is an amount equal to continuation of his base salary for a period of 18 months from the Separation Date and target bonus on a pro-rata basis for such 18-month period, in each case, to be paid on the Company's regular payroll schedule and less applicable withholdings and deductions; (ii) a cash payment of $376,200, which is an amount equal to Mr. Cory's target bonus for calendar year 2022; (iii) reimbursement for COBRA continuation coverage for Mr. Cory and his eligible dependents for a period of 18 months following the Separation Date, until Mr. Corey is no longer eligible for such continuation coverage or until Mr. Cory is eligible for coverage in connection with new employment, whichever is earliest; (iv) accelerated vesting of 50% of Mr. Cory's unvested stock options, performance-based restricted stock units and time-based restricted stock units outstanding as of the Separation Date; and (v) reimbursement of Mr. Cory's legal fees associated with the negotiation of the Separation Agreement, in an amount up to $10,000 (collectively, the "Severance Benefits"). The Separation Agreement also provides that Mr. Cory will have a period of one year following the Separation Date to exercise vested stock options held as of the Separation Date and unexpired as of such exercise date. The Separation Agreement also contains a general release of claims against the Company, as well as other customary covenants. 

The above description of the terms of the Separation Agreement is not complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022.